Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
J Clin Endocrinol Metab. 2011 Dec;96(12):E2023-8. doi: 10.1210/jc.2010-1908. Epub 2011 Sep 21.
Circulating adiponectin has been inversely associated with risk for several malignancies. Its association with thyroid cancer has not yet been evaluated.
OBJECTIVE/METHODS: We measured circulating adiponectin levels in 175 thyroid carcinoma patients and 107 controls. We also examined the expression of adiponectin receptors (AdipoR1 and AdipoR2) using immunohistochemistry in 82 thyroid carcinoma tissues and using RT-qPCR in 40 human thyroid carcinoma tissues (32 papillary, six follicular/Hurthle, one anaplastic, one medullary), four normal human thyroid tissue specimens, and the BHP7 and SW579 thyroid cancer cell lines. We then utilized these thyroid cancer cell lines to investigate whether adiponectin could directly regulate cell cycle or apoptosis.
Thyroid cancer patients had lower circulating adiponectin levels than controls (17.00 ± 6.32 vs. 19.26 ± 6.28 μg/ml; P < 0.001). Subjects in the highest tertile of circulating adiponectin concentrations had significantly lower odds of developing any type of thyroid carcinoma (odds ratio = 0.29; 95% confidence interval, 0.16-0.55), or papillary thyroid carcinoma (odds ratio = 0.27; 95% confidence interval, 0.14-0.55), before and after adjustment for potential confounders. Both thyroid carcinoma cell lines and tissues expressed AdipoR1 and AdipoR2. Recombinant adiponectin did not exert a clinically significant direct effect on cell cycle, proliferation, or apoptosis in thyroid cancer cell lines in vitro.
Circulating adiponectin is independently and inversely associated with the risk of thyroid cancer. Human thyroid carcinomas and cell lines express adiponectin receptors. However, in the absence of a major direct effect of adiponectin on thyroid cancer cell lines in vitro, the negative association observed herein may be attributed to the metabolic effects of adiponectin.
循环脂联素与多种恶性肿瘤的风险呈负相关。其与甲状腺癌的关系尚未得到评估。
目的/方法：我们测量了 175 例甲状腺癌患者和 107 例对照者的循环脂联素水平。我们还使用免疫组织化学方法检测了 82 例甲状腺癌组织中的脂联素受体（AdipoR1 和 AdipoR2），并使用 RT-qPCR 检测了 40 例人甲状腺癌组织（32 例乳头状、6 例滤泡/ Hurthle 细胞癌、1 例间变性癌、1 例髓样癌）、4 例正常甲状腺组织标本和 BHP7 和 SW579 甲状腺癌细胞系中的 AdipoR1 和 AdipoR2。然后，我们利用这些甲状腺癌细胞系研究脂联素是否可以直接调节细胞周期或凋亡。
甲状腺癌患者的循环脂联素水平低于对照组（17.00±6.32 与 19.26±6.28μg/ml；P<0.001）。循环脂联素浓度最高的 tertile 患者发生任何类型甲状腺癌（比值比=0.29；95%置信区间，0.16-0.55）或甲状腺乳头状癌（比值比=0.27；95%置信区间，0.14-0.55）的可能性显著降低，调整潜在混杂因素前后。两种甲状腺癌细胞系和组织均表达 AdipoR1 和 AdipoR2。重组脂联素在体外对甲状腺癌细胞系的细胞周期、增殖或凋亡没有显著的直接作用。
循环脂联素与甲状腺癌的风险独立且呈负相关。人甲状腺癌和细胞系表达脂联素受体。然而，由于脂联素对甲状腺癌细胞系的体外无明显直接作用，本研究中观察到的负相关可能归因于脂联素的代谢作用。
